- Home
- NIPG vs SLS Comparison
NIPG vs SLS Comparison
Compare NIPG & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIPG
- SLS
- Stock Information
- Founded
- NIPG 2014
- SLS 2012
- Country
- NIPG Sweden
- SLS United States
- Employees
- NIPG N/A
- SLS N/A
- Industry
- NIPG
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- NIPG
- SLS Health Care
- Exchange
- NIPG NYSE
- SLS Nasdaq
- Market Cap
- NIPG 94.5M
- SLS 89.6M
- IPO Year
- NIPG 2024
- SLS N/A
- Fundamental
- Price
- NIPG $1.50
- SLS $1.56
- Analyst Decision
- NIPG Strong Buy
- SLS
- Analyst Count
- NIPG 1
- SLS 0
- Target Price
- NIPG $12.00
- SLS N/A
- AVG Volume (30 Days)
- NIPG 63.7K
- SLS 2.0M
- Earning Date
- NIPG 04-30-2025
- SLS 05-20-2025
- Dividend Yield
- NIPG N/A
- SLS N/A
- EPS Growth
- NIPG N/A
- SLS N/A
- EPS
- NIPG N/A
- SLS N/A
- Revenue
- NIPG $85,266,306.00
- SLS N/A
- Revenue This Year
- NIPG $20.82
- SLS N/A
- Revenue Next Year
- NIPG $29.70
- SLS N/A
- P/E Ratio
- NIPG N/A
- SLS N/A
- Revenue Growth
- NIPG 1.91
- SLS N/A
- 52 Week Low
- NIPG $0.99
- SLS $0.77
- 52 Week High
- NIPG $17.76
- SLS $1.85
- Technical
- Relative Strength Index (RSI)
- NIPG N/A
- SLS 61.26
- Support Level
- NIPG N/A
- SLS $1.60
- Resistance Level
- NIPG N/A
- SLS $1.85
- Average True Range (ATR)
- NIPG 0.00
- SLS 0.13
- MACD
- NIPG 0.00
- SLS 0.02
- Stochastic Oscillator
- NIPG 0.00
- SLS 50.85
About NIPG NIP GROUP INC SPON ADS EACH REPR 2 CL A ORD SHS
NIP Group Inc is a digital entertainment company built for the growing gaming and esports industry. NIP Group integrates multiple businesses such as talent agency, event production, game-themed hotels and game publishing to create transformative entertainment experiences that inspire, connect fans, expand global influence, and achieve deep interaction on platforms where digital native players gather. It currently has operation centers in Sweden, China, Abu Dhabi, and Brazil, and its esports teams cover multiple game projects and are active in the top event stages.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.